Arovella Therapeutics Limited · ASX:ALA

Arovella Therapeutics — Shareholder Meeting (December 2021)

17 slides from Arovella Therapeutics's shareholder meeting presentation, Dec 16, 2021

  1. Slide 1: Annual General Meeting

    ASX: ALA ANNUAL GENERAL MEETING December 2021

  2. Slide 2: Experienced Senior Leadership Team

    Experienced Senior Leadership Team Paul Hopper Dr. Michael Baker Dr. Debora Barton CHAIRMAN CEO & MANAGING DIRECTOR DIRECTOR Over 25 years experience in the medical, Over 15 years experience in scientific Over 20 years of oncology experience, in healthcare & life sciences sectors. Focussed research,

  3. Slide 3: The Year In Review

    Professor Karadimitris The Year In Review SUDA enters into Research appointed Chair of the SAB Plasmid and Lentivirus Agreement with Imperial AUG 2021 manufacturer selected AUG 2021 Appointed DEC 2021 Dr Debora Barton - NED MTPK terminates MTPS ZolpiMist Agreement Arovella selected to AUG 2021 termi

  4. Slide 4: Arovella Company Overview

    Arovella Company Overview Financial Snapshot ALA Price and Volume - 12 Months1 ASX CODE ALA 40000000 0.08 Market capitalisation1 $19.2 million 35000000 0.07 Shares on issue 480.82 million 30000000 52-week low / high $0.033 / $0.075 0.06 Cash (30 September 2021) $5.1 million 25000000 0.05 20000000 Ma

  5. Slide 5: Introducing Arovella Therapeutics

    Introducing Arovella Therapeutics Committed to helping people live longer and healthier lives ASX: ALA 5 © Copyright SUDA Pharmaceuticals Ltd 2021

  6. Slide 6: iNKT Cell Therapy A Transformational Deal

    iNKT Cell Therapy A Transformational Deal  The iNKT cell therapy platform is at the cutting edge of cancer treatment  The technology was developed by Professor Karadimitris at Imperial College London – a top 10 university  Arovella is one of four companies worldwide and the only ASX-listed compan

  7. Slide 7: Commercial Activity for iNKT Cell Players

    Commercial Activity for iNKT Cell Players Strategic Partnership Market Cap Acquisition Value US$875m Total1 US$172m2 US$185m Total3 Market Cap Preclinical Phase 1 Phase 1 AU$19.2m2 Preclinical May 2021 – Appia Bio October 2021 – MiNK May 2021 – Kuur June 2021 – Acquired raised US$52m in their Therap

  8. Slide 8: Expanding the Platform DKK1 mAb from MD Anderson

    Expanding the Platform DKK1 mAb from MD Anderson  The DKK1 mAb was developed at MD Anderson and can be incorporated into a chimeric antigen receptor (CAR) Already Completed Arovella To Complete  DKK1 is increased in many cancer types1 o Multiple myeloma (Blood Cancer) o Pancreatic cancer o Breast

  9. Slide 9: DKK1-CAR-T Cells Work Against Many Cancers

    DKK1-CAR-T Cells Work Against Many Cancers Multiple Myeloma1 Lung Cancer2 Triple Negative Pancreatic Cancer5 Breast Cancer3,4 34,900 cases in 235,760 cases in 60,400 cases the US per annum the US per annum 28,150 cases in the US per annum in the US per annum 55.6% 5-year 21.7% 5-year 10.8% 5-year su

  10. Slide 10: CAR-iNKT Cell Therapy Development

    CAR-iNKT Cell Therapy Development  Enter into Research Agreement with Imperial College London   Recruit cell therapy manufacturing expert – Dr. Sandhya Buchanan   Recruit domain expertise board members – Dr. Debora Barton & Dr. Liz Stoner   Expand Scientific Advisory Board – Prof. Tassos Kara

  11. Slide 11: ZolpiMist - Short-term Insomnia

    ZolpiMist® - Short-term Insomnia  ZolpiMist is Arovella’s oral spray version of the insomnia drug Ambien/Stilnox, Sanofi’s blockbuster1  Short-term insomnia has an estimated prevalence of 9.5% in the US2  Sleep problems rose from 16% to 25% during the COVID-19 pandemic (University of Southampton)

  12. Slide 12: Arovella Therapeutics Pipeline

    Arovella Therapeutics Pipeline Cell Therapy INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE2/31 PARTNER ALA-101 CD19 expressing CD19 Expressing Lymphoma (CAR19-iNKT) cancers ALA-102 Not Disclosed ND ALA-103 Not disclosed ND ALA-104 Multiple (DKK1-CAR-iNKT) Myeloma Multiple Myeloma & Solid Tumours Oro

  13. Slide 13: Arovella Therapeutics Summary

    Arovella Therapeutics Summary World Class Leadership Two Transformational Deals Unique ASX Listed Cell Therapy Arovella has a leadership group with Arovella has licenced in a unique Arovella is the only ASX-Listed company working extensive drug development experience, platform and an additional CAR

  14. Slide 14: Q&A

    Q&A © Copyright Arovella Therapeutics Ltd 2021

  15. Slide 15: Thank You

    Thank You Dr. Michael Baker CEO & Managing Director Email: mbaker@arovella.com Mobile: +61 403 468 187 © Copyright Arovella Therapeutics Ltd 2021

  16. Slide 16: Committed to helping people live longer and healthier lives

    Committed to helping people live longer and healthier lives Patient-Centric It starts with the end in mind. In our case, it is our patients. At Arovella, we are invested in making a positive difference in helping patients live longer and healthier lives. Creating a brighter future for people is our

  17. Slide 17: Disclaimer

    Disclaimer 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Arovella Therapeutics Limited (Company). In prepa

Arovella Therapeutics — Shareholder Meeting (December 2021) on 6ix